Nadziakiewicz Paulina, Szczurek-Wasilewicz Wioletta, Szyguła-Jurkiewicz Bożena
Student's Scientific Society, 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
Department of Pharmacology, Faculty of Medicine, University of Opole, 45-052 Opole, Poland.
Pharmaceuticals (Basel). 2024 Dec 30;18(1):32. doi: 10.3390/ph18010032.
Heart failure (HF) is a common condition and one of the main morbidity and mortality factors in elderly patients. The incidence of HF progressively increases with age, reaching >10% in those aged 70 years or over. In the elderly population, both the diagnosis and the management of HF prove challenging, often requiring specialized care and a multidisciplinary approach. In seniors, atypical presentation of HF is much more common than in younger patients; thus, a holistic assessment with biomarkers related to HF allows for early diagnosis and accurate risk stratification in this group of patients. This article reviews the clinical and diagnostic differences in elderly patients with HF, highlighting the presence of comorbidities, frailty, cognitive impairment, and polypharmacy, as well as discussing potential biomarkers that may have clinical application in this population.
心力衰竭(HF)是一种常见病症,也是老年患者主要的发病和死亡因素之一。HF的发病率随年龄增长而逐渐升高,在70岁及以上人群中发病率超过10%。在老年人群中,HF的诊断和管理颇具挑战性,通常需要专业护理和多学科方法。与年轻患者相比,老年患者HF的非典型表现更为常见;因此,通过与HF相关的生物标志物进行全面评估,有助于对该组患者进行早期诊断和准确的风险分层。本文综述了老年HF患者的临床和诊断差异,强调了合并症、虚弱、认知障碍和多重用药的存在,并讨论了可能在该人群中具有临床应用价值的潜在生物标志物。